Author:
Gómez-Martínez Sofia,Morgado-Carrasco Daniel
Reference4 articles.
1. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study;Kimball;J Eur Acad Dermatol Venereol,2013
2. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: week 104 results from the non-interventional, prospective, German multicentre PERSIST study;Gerdes;J Eur Acad Dermatol Venereol,2023
3. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis;Yiu;JAMA Dermatol,2022
4. Off-label uses of ustekinumab;Ye;Dermatol Ther,2022